Lv3
220 积分 2024-06-30 加入
Mismatch repair status and benefit from adjuvant bevacizumab in colon cancer: exploratory analysis of NSABP C-08
2天前
已关闭
Sargent DJ, Mahmoud NN, Allegra CJ, et al. Mismatch repair status and benefit from adjuvant bevacizumab in colon cancer: exploratory analysis of NSABP C-08
2天前
已关闭
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
2天前
已完结
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
1个月前
已完结
替雷利珠单抗联合贝伐珠单抗治疗驱动基因阴性、拒绝化疗晚期非鳞NSCLC的临床观察
4个月前
已关闭
Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine–oxaliplatin versus short-course radiotherapy followed by capecitabine–oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial
8个月前
已完结
局部晚期直肠癌患者中短程放疗后信迪利单抗联合卡培他滨-奥沙利铂与短程放疗后卡培他滨-奥沙利铂的全新辅助治疗 （SPRING-01）：一项单中心、开放标签、2 期随机对照试验
8个月前
已完结
皖公网安备34019202002308
